Discover how pharma forecasting teams can navigate Loss of Exclusivity (LoE) with precision. Learn strategies to manage asset saturation, biosimilar impact, and regional planning in today’s competitive pipeline landscape.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
The lines between orphan drugs and mainstream prescription drugs are blurring. In this infographic, we look at the top orphan drugs and the wider market for drugs for rare diseases.| Evaluate
Orphan drugs for rare diseases are set to make up one fifth of the of all prescription drug sales by 2030. This report investigates the orphan drug landscape out to 2030.| Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
2024 Review of Pharma - Analysis of the state of dealmaking, investment & stock price performance of the biopharma sector in 2024| Evaluate
